ArticleFrontiers in nutrition2025
Association between albumin to globulin ratio and all-cause and cardiovascular mortality among individuals with cardiovascular-kidney-metabolic syndrome: results from NHANES 2003 to 2018.
Article in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Association between the albumin-to-globulin ratio and deep vein thrombosis in older adults receiving home healthcare: a prospective cohort study.Irish journal of medical science · 2026Article
- Cardiovascular-kidney-metabolic syndrome: a comprehensive review of pathophysiology, epidemiology, diagnosis, and management.Cardiovascular diabetology · 2026Review
- Emerging multidimensional biomarker system for cardiovascular-kidney-metabolic syndrome: from multi-omics integration to clinical artificial intelligence.Cardiovascular diabetology · 2026Review
- Serum Albumin Level Predicts Systemic Arterial Stiffening Mediated Partially by Change in Lean Body Mass: A Retrospective Cohort Study in General Japanese Population.Vascular health and risk management · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The albumin-to-globulin ratio (AGR) is a promising biomarker for inflammation and nutritional status. However, its association with mortality in individuals with Cardiovascular-Kidney-Metabolic (CKM) syndrome remains underexplored. This study investigates the relationship between AGR and mortality outcomes in CKM syndrome, aiming to provide insights for risk assessment and management in this population. Methods: We conducted a cohort study utilizing data from the National Health and Nutrition Examination Survey (NHANES) 2003-2018, with mortality follow-up through 31 December 2019. Survey-weighted multivariable Cox hazards regression models assessed the associations between AGR and all-cause and cardiovascular disease (CVD) mortality. Nonlinear relationships and threshold effects were evaluated using smooth curve fitting and piecewise linear regression. Sensitivity analyses, subgroup analyses, and interaction tests were further performed to validate the findings. Results: Over a median follow-up of 8.33 years, 1,745 all-cause deaths occurred, including 534 CVD-related deaths. After multivariable adjustment, a significant inverse dose-response relationship was observed between AGR and both all-cause and CVD mortality. Specifically, a nonlinear association was identified for all-cause mortality, with an inflection point at an AGR of 1.26, whereas the relationship with CVD mortality remained linear. Compared with the lowest AGR quartile, individuals in the highest AGR quartile had multivariable-adjusted hazard ratios (HR) of 0.55 (95% CI: 0.45-0.67) for all-cause mortality and 0.47 (95% CI: 0.34-0.64) for CVD mortality (P trend < 0.0001 for both outcomes). Each one-unit increase in AGR was associated with a 62% reduction in the risk of all-cause death and a 73% reduction in the risk of CVD mortality. The inverse association with all-cause mortality was more pronounced among individuals under 60 years, daily smokers, Mexican Americans and those in CKM stage 1, while the association with CVD mortality was stronger among individuals with a college degree, those under 60 years, and daily smokers. Sensitivity analyses confirmed these findings. Conclusion: Higher AGR is significantly associated with reduced risks of both all-cause and CVD mortality in the CKM syndrome population. Notably, while the relationship with all-cause mortality is nonlinear, the association with CVD mortality follows a linear pattern. These findings suggest that AGR could serve as a valuable biomarker for mortality risk stratification in CKM syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.